Focusing in on use of pharmacokinetic profiles in routine hemophilia care-Reference-Cited by-同舟云学术

Focusing in on use of pharmacokinetic profiles in routine hemophilia care

Published:2018-05-27 Issue:3 Volume:2 Page:607-614
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

Croteau Stacy E.¹^ORCID,Callaghan Michael U.²^ORCID,Davis Joanna³,Dunn Amy L.⁴,Guerrera Michael⁵,Khan Osman⁶,Neufeld Ellis J.⁷,Raffini Leslie J.⁸,Recht Michael⁹,Wang Michael¹⁰,Iorio Alfonso¹¹¹²^ORCID

Affiliation:

1. Boston Hemophilia Center; Boston Children’s Hospital; Boston MA USA

2. Wayne State University; Detroit MI USA

3. University of Miami School of Medicine; Miami FL USA

4. Nationwide Children’s Hospital Division of Hematology/Oncology/BMT; The Ohio State University School of Medicine; Columbus OH USA

5. Children’s National Health System; Washington DC USA

6. University of Oklahoma Health Sciences Center; Oklahoma City OK USA

7. St. Jude Children’s Research Hospital; Memphis TN USA

8. The Children’s Hospital of Philadelphia; Philadelphia PA USA

9. The Hemophilia Center at Oregon Health & Science University; Portland OR USA

10. University of Colorado Hemophilia and Thrombosis Center; Aurora CO USA

11. Department of Health Research Methods, Evidence, and Impact; McMaster University; Hamilton ON Canada

12. Department of Medicine; McMaster University; Hamilton ON Canada

Funder

Pfizer

Publisher

Wiley

Subject

Hematology

Reference18 articles.

1. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia;Manco-Johnson;N Engl J Med,2007

2. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study;Tagliaferri;Thromb Haemost,2015

3. European retrospective study of real-life haemophilia treatment;Berntorp;Haemophilia,2017

4. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s;Fischer;Blood,2013

5. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol;Iorio;JMIR Res Protoc,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting joint involvement through tailored prophylaxis in severe haemophilia A, is it possible?;Haemophilia;2024-04-04

2. Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B;Research and Practice in Thrombosis and Haemostasis;2024-03

3. Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment;Seminars in Thrombosis and Hemostasis;2024-01-15

4. The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators;Blood Reviews;2023-09

5. Perspective – The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021;Blood Reviews;2021-11